Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

101 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
Kaltenthaler E, Tappenden P, Booth A, Akehurst R. Kaltenthaler E, et al. Among authors: tappenden p. Health Policy. 2008 Sep;87(3):389-400. doi: 10.1016/j.healthpol.2008.02.007. Epub 2008 Apr 2. Health Policy. 2008. PMID: 18387689
Improving Transparency in Decision Models: Current Issues and Potential Solutions.
Tappenden P, Caro JJ. Tappenden P, et al. Pharmacoeconomics. 2019 Nov;37(11):1303-1304. doi: 10.1007/s40273-019-00850-0. Pharmacoeconomics. 2019. PMID: 31642021 No abstract available.
A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway.
Jin H, Tappenden P, Robinson S, Achilla E, MacCabe JH, Aceituno D, Byford S. Jin H, et al. Among authors: tappenden p. Pharmacoeconomics. 2020 Jun;38(6):537-555. doi: 10.1007/s40273-020-00895-6. Pharmacoeconomics. 2020. PMID: 32144726 Review.
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Chilcott J, Wight J, Lloyd Jones M, Tappenden P. Chilcott J, et al. Among authors: tappenden p. Health Technol Assess. 2001;5(19):1-61. doi: 10.3310/hta5190. Health Technol Assess. 2001. PMID: 11701097 Review. No abstract available.
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Chilcott J, Tappenden P, Jones ML, Wight JP. Chilcott J, et al. Among authors: tappenden p. Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791. doi: 10.1016/s0149-2918(00)80078-8. Clin Ther. 2001. PMID: 11768834 Review.
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Chilcott J, et al. Among authors: tappenden p. BMJ. 2003 Mar 8;326(7388):522; discussion 522. doi: 10.1136/bmj.326.7388.522. BMJ. 2003. PMID: 12623909 Free PMC article.
A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.
Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, Tappenden P. Chilcott J, et al. Among authors: tappenden p. Health Technol Assess. 2003;7(4):iii-62. doi: 10.3310/hta7040. Health Technol Assess. 2003. PMID: 12633527 Review. No abstract available.
The role of modelling in prioritising and planning clinical trials.
Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. Chilcott J, et al. Among authors: tappenden p. Health Technol Assess. 2003;7(23):iii, 1-125. doi: 10.3310/hta7230. Health Technol Assess. 2003. PMID: 14499052 Review.
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C. Tappenden P, et al. Health Technol Assess. 2004 Jun;8(27):iii, 1-78. doi: 10.3310/hta8270. Health Technol Assess. 2004. PMID: 15215017 Review.
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C. Chilcott J, et al. Among authors: tappenden p. BJOG. 2004 Sep;111(9):903-7. doi: 10.1111/j.1471-0528.2004.00226.x. BJOG. 2004. PMID: 15327602
101 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page